CAIX PET/CT for Residual or Recurrent Post-ablative ccRCC

NCT ID: NCT07077083

Last Updated: 2025-07-22

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: PHASE2
• Total Enrollment: 10 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-08-01
• Study Completion Date: 2028-08-01

Brief Summary

The goal of this clinical trial is to learn whether 89Zr-Girentuximab PET scans can inform management of renal cell carcinoma. The main questions it aims to answer are:

• Does the 89Zr-Girentuximab PET detect ccRCC that is left behind or has come back after treatment?
• What differences can be seen on the 89Zr-Girentuximab PET before and after standard of care treatment?

Participants in arm 1 will be given the study drug followed by a PET scan 3-7 days after injection. Participants in arm 2 will receive the same, but will proceed with their standard of care cryoablation after the initial PET scan. Within 3 days of the cryoablation treatment, participants will receive a repeat PET scan.

Conditions

Clear Cell Renal Cell Carcinoma (ccRCC); ccRCC

Study Design

• Allocation Method: NON_RANDOMIZED
• Intervention Model: PARALLEL
• Primary Study Purpose: DIAGNOSTIC
• Blinding Strategy: NONE

Study Groups

Patients with known or suspected recurrent or residual ccRCC

PET and Histological correlation

Group Type: EXPERIMENTAL

89Zr-Girentuximab

Intervention Type: DRUG

89Zr-Girentuximab PET

Patients with ccRCC undergoing ablation

PET for evaluation of post-ablative kidney

Group Type: EXPERIMENTAL

89Zr-Girentuximab

Intervention Type: DRUG

89Zr-Girentuximab PET

Interventions

89Zr-Girentuximab

89Zr-Girentuximab PET

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Written and voluntarily given Informed Consent

2. ≥18 years of age at time of consent

a. Because no dosing or adverse event data are currently available on the use of 89Zr-girentuximab in participants <18 years of age, children are excluded from this study, but will be eligible for future pediatric trials.

3. Have the capacity to understand the study and be willing and able to comply with all protocol requirements.

4. Findings suspicious for post-ablation residual or recurrent ccRCC (subjects in cohort 1) documented at conventional imaging or biopsy, performed within 90 days prior to 89Zr-girentuximab PET scan.

5. Findings suspicious for primary ccRCC (subjects in cohort 2) documented at standard histology or conventional imaging, performed within 90 days prior to 89Zr-girentuximab PET scan.

6. Negative serum or urine pregnancy tests in female patients of childbearing potential within 72 hours prior to receiving 89Zr-girentuximab. Female patients of non-child bearing potential must provide evidence by fulfilling one of the following criteria at screening:

1. Post-menopausal defined as aged more than 50 years and amenorrheic for at least 12 months following cessation of all exogenous hormonal treatments

2. Women under 50 years old would be consider postmenopausal if they have been amenorrheic for 12 months or more following cessation of exogenous hormonal treatments and with luteinizing hormone (LH) and follicle-stimulating hormone (FSH) levels in the post-menopausal range for the institution

3. Documentation of irreversible surgical sterilization by hysterectomy, bilateral oophorectomy, or bilateral salpingectomy but not tubal ligation

7. For all participants, consent to practice double-barrier contraception until a minimum of 42 days after 89Zr-girentuximab administration.

Exclusion Criteria

1. Renal mass known to be a metastasis of another primary tumor.

2. Active non-renal malignancy requiring therapy during and up to EOT visit.

3. Planned antineoplastic therapies (for the period between IV administration of 89Zr-girentuximab and imaging).

4. Previous administration of any radionuclide within 10 of its half-lives before 89Zr-girentuximab injection day.

5. Serious non-malignant disease (e.g., psychiatric, infectious, autoimmune, or metabolic), that may interfere with the objectives of the program or with the safety or compliance of the subject, as judged by the Investigator.

6. Mental impairment that may compromise the ability to give informed consent and comply with the requirements of the program.

7. Women who are pregnant or breastfeeding.

8. Known hypersensitivity to girentuximab or DFO (desferoxamine).

9. Renal insufficiency with estimated glomerular filtration rate eGFR ≤ 40 mL/min/ 1.73 m²

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Telix Pharmaceuticals, Ltd

UNKNOWN

Sponsor Role: collaborator

Massachusetts General Hospital

OTHER

Sponsor Role: lead

Responsible Party

Shadi Abdar Esfahani

Director of Nuclear Medicine Clinical Trials

Responsibility Role: PRINCIPAL_INVESTIGATOR

Principal Investigators

Shadi Abdar Esfahani, MD, MPH

Role: PRINCIPAL_INVESTIGATOR

Massachusetts General Hospital

Locations

Massachusetts General Hospital

Boston, Massachusetts, United States

Countries

United States

Central Contacts

Taylor McVeigh

Role: CONTACT

tmcveigh@mgh.harvard.edu

6177261312

Facility Contacts

Taylor McVeigh

Role: primary

tmcveigh@mgh.harvard.edu

6177261312

Other Identifiers

25-240

Identifier Type: -

Identifier Source: org_study_id